CovidFranceV1, Main, Exploration, bibRecord, 000006

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Identifieur interne : 000006 ( Main/Exploration ); précédent : 000005; suivant : 000007

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Auteurs : John Billington [Belgique] ; Isabelle Deschamps [France] ; Stanley C. Erck [États-Unis] ; Julie L. Gerberding [États-Unis] ; Emmanuel Hanon [Belgique] ; Sabrina Ivol [Pays-Bas] ; John W. Shiver [France] ; Julia A. Spencer [États-Unis] ; Johan Van Hoof [Pays-Bas]

Source :

Health security [ 2326-5108 ]

RBID : pubmed:32348165

Descripteurs français

KwdFr :
- Agrément de médicaments (MeSH), Contrôle des maladies transmissibles (organisation et administration), Développement de médicament (MeSH), Femelle (MeSH), Humains (MeSH), Industrie pharmaceutique (organisation et administration), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (épidémiologie), Maladies transmissibles émergentes (prévention et contrôle), Maladies transmissibles émergentes (épidémiologie), Mesures de sécurité (MeSH), Mâle (MeSH), Pandémies (prévention et contrôle), Pandémies (statistiques et données numériques), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (épidémiologie), Santé mondiale (MeSH), Santé publique (MeSH), Technologie pharmaceutique (organisation et administration), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (pharmacologie), Évaluation des besoins (MeSH).
MESH :
- administration et posologie : Vaccins antigrippaux.
- organisation et administration : Contrôle des maladies transmissibles, Industrie pharmaceutique, Technologie pharmaceutique.
- pharmacologie : Vaccins antigrippaux.
- prévention et contrôle : Infections à coronavirus, Maladies transmissibles émergentes, Pandémies, Pneumopathie virale.
- statistiques et données numériques : Pandémies.
- épidémiologie : Infections à coronavirus, Maladies transmissibles émergentes, Pneumopathie virale.
- Agrément de médicaments, Développement de médicament, Femelle, Humains, Mesures de sécurité, Mâle, Santé mondiale, Santé publique, Évaluation des besoins.

English descriptors

KwdEn :
- Communicable Disease Control (organization & administration), Communicable Diseases, Emerging (epidemiology), Communicable Diseases, Emerging (prevention & control), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Drug Approval (MeSH), Drug Development (MeSH), Drug Industry (organization & administration), Female (MeSH), Global Health (MeSH), Humans (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (pharmacology), Male (MeSH), Needs Assessment (MeSH), Pandemics (prevention & control), Pandemics (statistics & numerical data), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Public Health (MeSH), Security Measures (MeSH), Technology, Pharmaceutical (organization & administration).
MESH :
- chemical , administration & dosage : Influenza Vaccines.
- epidemiology : Communicable Diseases, Emerging, Coronavirus Infections, Pneumonia, Viral.
- organization & administration : Communicable Disease Control, Drug Industry, Technology, Pharmaceutical.
- chemical , pharmacology : Influenza Vaccines.
- prevention & control : Communicable Diseases, Emerging, Coronavirus Infections, Pandemics, Pneumonia, Viral.
- statistics & numerical data : Pandemics.
- Drug Approval, Drug Development, Female, Global Health, Humans, Male, Needs Assessment, Public Health, Security Measures.

Abstract

The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.

DOI: 10.1089/hs.2020.0043
PubMed: 32348165
PubMed Central: PMC7310201

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001536
to stream Main, to step Curation: 001536

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.</title>
<author><name sortKey="Billington, John" sort="Billington, John" uniqKey="Billington J" first="John" last="Billington">John Billington</name>
<affiliation wicri:level="1"><nlm:affiliation>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Deschamps, Isabelle" sort="Deschamps, Isabelle" uniqKey="Deschamps I" first="Isabelle" last="Deschamps">Isabelle Deschamps</name>
<affiliation wicri:level="3"><nlm:affiliation>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erck, Stanley C" sort="Erck, Stanley C" uniqKey="Erck S" first="Stanley C" last="Erck">Stanley C. Erck</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gerberding, Julie L" sort="Gerberding, Julie L" uniqKey="Gerberding J" first="Julie L" last="Gerberding">Julie L. Gerberding</name>
<affiliation wicri:level="2"><nlm:affiliation>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hanon, Emmanuel" sort="Hanon, Emmanuel" uniqKey="Hanon E" first="Emmanuel" last="Hanon">Emmanuel Hanon</name>
<affiliation wicri:level="1"><nlm:affiliation>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ivol, Sabrina" sort="Ivol, Sabrina" uniqKey="Ivol S" first="Sabrina" last="Ivol">Sabrina Ivol</name>
<affiliation wicri:level="3"><nlm:affiliation>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shiver, John W" sort="Shiver, John W" uniqKey="Shiver J" first="John W" last="Shiver">John W. Shiver</name>
<affiliation wicri:level="3"><nlm:affiliation>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spencer, Julia A" sort="Spencer, Julia A" uniqKey="Spencer J" first="Julia A" last="Spencer">Julia A. Spencer</name>
<affiliation wicri:level="2"><nlm:affiliation>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Van Hoof, Johan" sort="Van Hoof, Johan" uniqKey="Van Hoof J" first="Johan" last="Van Hoof">Johan Van Hoof</name>
<affiliation wicri:level="3"><nlm:affiliation>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 May/Jun</date>
<idno type="RBID">pubmed:32348165</idno>
<idno type="pmid">32348165</idno>
<idno type="doi">10.1089/hs.2020.0043</idno>
<idno type="pmc">PMC7310201</idno>
<idno type="wicri:Area/Main/Corpus">001536</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001536</idno>
<idno type="wicri:Area/Main/Curation">001536</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001536</idno>
<idno type="wicri:Area/Main/Exploration">001536</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.</title>
<author><name sortKey="Billington, John" sort="Billington, John" uniqKey="Billington J" first="John" last="Billington">John Billington</name>
<affiliation wicri:level="1"><nlm:affiliation>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Deschamps, Isabelle" sort="Deschamps, Isabelle" uniqKey="Deschamps I" first="Isabelle" last="Deschamps">Isabelle Deschamps</name>
<affiliation wicri:level="3"><nlm:affiliation>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erck, Stanley C" sort="Erck, Stanley C" uniqKey="Erck S" first="Stanley C" last="Erck">Stanley C. Erck</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gerberding, Julie L" sort="Gerberding, Julie L" uniqKey="Gerberding J" first="Julie L" last="Gerberding">Julie L. Gerberding</name>
<affiliation wicri:level="2"><nlm:affiliation>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Hanon, Emmanuel" sort="Hanon, Emmanuel" uniqKey="Hanon E" first="Emmanuel" last="Hanon">Emmanuel Hanon</name>
<affiliation wicri:level="1"><nlm:affiliation>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ivol, Sabrina" sort="Ivol, Sabrina" uniqKey="Ivol S" first="Sabrina" last="Ivol">Sabrina Ivol</name>
<affiliation wicri:level="3"><nlm:affiliation>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shiver, John W" sort="Shiver, John W" uniqKey="Shiver J" first="John W" last="Shiver">John W. Shiver</name>
<affiliation wicri:level="3"><nlm:affiliation>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Spencer, Julia A" sort="Spencer, Julia A" uniqKey="Spencer J" first="Julia A" last="Spencer">Julia A. Spencer</name>
<affiliation wicri:level="2"><nlm:affiliation>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
<wicri:cityArea>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Van Hoof, Johan" sort="Van Hoof, Johan" uniqKey="Van Hoof J" first="Johan" last="Van Hoof">Johan Van Hoof</name>
<affiliation wicri:level="3"><nlm:affiliation>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden</wicri:regionArea>
<placeName><settlement type="city">Leyde</settlement>
<region nuts="2" type="province">Hollande-Méridionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Health security</title>
<idno type="eISSN">2326-5108</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Communicable Disease Control (organization & administration)</term>
<term>Communicable Diseases, Emerging (epidemiology)</term>
<term>Communicable Diseases, Emerging (prevention & control)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (prevention & control)</term>
<term>Drug Approval (MeSH)</term>
<term>Drug Development (MeSH)</term>
<term>Drug Industry (organization & administration)</term>
<term>Female (MeSH)</term>
<term>Global Health (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Influenza Vaccines (administration & dosage)</term>
<term>Influenza Vaccines (pharmacology)</term>
<term>Male (MeSH)</term>
<term>Needs Assessment (MeSH)</term>
<term>Pandemics (prevention & control)</term>
<term>Pandemics (statistics & numerical data)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (prevention & control)</term>
<term>Public Health (MeSH)</term>
<term>Security Measures (MeSH)</term>
<term>Technology, Pharmaceutical (organization & administration)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Agrément de médicaments (MeSH)</term>
<term>Contrôle des maladies transmissibles (organisation et administration)</term>
<term>Développement de médicament (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Industrie pharmaceutique (organisation et administration)</term>
<term>Infections à coronavirus (prévention et contrôle)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Maladies transmissibles émergentes (prévention et contrôle)</term>
<term>Maladies transmissibles émergentes (épidémiologie)</term>
<term>Mesures de sécurité (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Pandémies (prévention et contrôle)</term>
<term>Pandémies (statistiques et données numériques)</term>
<term>Pneumopathie virale (prévention et contrôle)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Santé mondiale (MeSH)</term>
<term>Santé publique (MeSH)</term>
<term>Technologie pharmaceutique (organisation et administration)</term>
<term>Vaccins antigrippaux (administration et posologie)</term>
<term>Vaccins antigrippaux (pharmacologie)</term>
<term>Évaluation des besoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Communicable Diseases, Emerging</term>
<term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Contrôle des maladies transmissibles</term>
<term>Industrie pharmaceutique</term>
<term>Technologie pharmaceutique</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Communicable Disease Control</term>
<term>Drug Industry</term>
<term>Technology, Pharmaceutical</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Communicable Diseases, Emerging</term>
<term>Coronavirus Infections</term>
<term>Pandemics</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Maladies transmissibles émergentes</term>
<term>Pandémies</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Pandémies</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Maladies transmissibles émergentes</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Approval</term>
<term>Drug Development</term>
<term>Female</term>
<term>Global Health</term>
<term>Humans</term>
<term>Male</term>
<term>Needs Assessment</term>
<term>Public Health</term>
<term>Security Measures</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Agrément de médicaments</term>
<term>Développement de médicament</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mesures de sécurité</term>
<term>Mâle</term>
<term>Santé mondiale</term>
<term>Santé publique</term>
<term>Évaluation des besoins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32348165</PMID>
<DateCompleted><Year>2020</Year>
<Month>07</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>07</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2326-5108</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>3</Issue>
<PubDate><MedlineDate>2020 May/Jun</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Health security</Title>
<ISOAbbreviation>Health Secur</ISOAbbreviation>
</Journal>
<ArticleTitle>Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.</ArticleTitle>
<Pagination><MedlinePgn>241-249</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1089/hs.2020.0043</ELocationID>
<Abstract><AbstractText>The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise that requires substantial upfront planning and offers no guarantee of success. EIDs are a particularly challenging target for global health preparedness, including for vaccine development. Insufficient attention has been given to challenges, lessons learned, and potential solutions to support and sustain vaccine industry engagement in vaccine development for EIDs. Drawing from lessons from the most recent Ebola epidemic in the Democratic Republic of the Congo, as well as the 2009 H1N1 influenza, 2014-2016 Ebola, and 2015-16 Zika outbreaks preceding it, we offer our perspective on challenges facing EID vaccine development and recommend additional solutions to prioritize in the near term. The 6 recommendations focus on reducing vaccine development timelines and increasing business certainty to reduce risks for companies. The global health security community has an opportunity to build on the current momentum to design a sustainable model for EID vaccines.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Billington</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deschamps</LastName>
<ForeName>Isabelle</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Erck</LastName>
<ForeName>Stanley C</ForeName>
<Initials>SC</Initials>
<AffiliationInfo><Affiliation>Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gerberding</LastName>
<ForeName>Julie L</ForeName>
<Initials>JL</Initials>
<AffiliationInfo><Affiliation>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hanon</LastName>
<ForeName>Emmanuel</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ivol</LastName>
<ForeName>Sabrina</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shiver</LastName>
<ForeName>John W</ForeName>
<Initials>JW</Initials>
<AffiliationInfo><Affiliation>Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Spencer</LastName>
<ForeName>Julia A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Van Hoof</LastName>
<ForeName>Johan</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Health Secur</MedlineTA>
<NlmUniqueID>101654694</NlmUniqueID>
<ISSNLinking>2326-5094</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName>
<QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName>
<QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012637" MajorTopicYN="N">Security Measures</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013678" MajorTopicYN="N">Technology, Pharmaceutical</DescriptorName>
<QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Epidemic management/response</Keyword>
<Keyword MajorTopicYN="N">Infectious diseases</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">Vaccine development</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>7</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32348165</ArticleId>
<ArticleId IdType="doi">10.1089/hs.2020.0043</ArticleId>
<ArticleId IdType="pmc">PMC7310201</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Lancet. 2017 Feb 4;389(10068):505-518</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28017403</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2015 Oct;13(10):651-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26373373</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2016 Sep;15(9):1075-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27181597</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013;8(3):e57755</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23526951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2019 Mar 28;10:549</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30984169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2018 Oct;17(10):913-923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30269612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2017 Jul 14;357(6347):153-156</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28706038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Glob Health. 2018 Dec;6(12):e1386-e1396</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30342925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2018 Apr 10;319(14):1431-1432</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29566112</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Trials. 2016 Feb;13(1):49-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26768572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2018 Nov 22;218(suppl_5):S698-S704</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30321368</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 May 8;58(17):453-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19444146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trop Med Infect Dis. 2019 Jul 14;4(3):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31337115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Jul 24;35(33):4064-4071</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28647170</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Aug 16;35(35 Pt A):4480-4485</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28347504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2018 May 31;378(22):2057-2060</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29847763</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Belgique</li>
<li>France</li>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Hollande-Méridionale</li>
<li>Maryland</li>
<li>New Jersey</li>
<li>Rhône-Alpes</li>
</region>
<settlement><li>Leyde</li>
<li>Lyon</li>
</settlement>
</list>
<tree><country name="Belgique"><noRegion><name sortKey="Billington, John" sort="Billington, John" uniqKey="Billington J" first="John" last="Billington">John Billington</name>
</noRegion>
<name sortKey="Hanon, Emmanuel" sort="Hanon, Emmanuel" uniqKey="Hanon E" first="Emmanuel" last="Hanon">Emmanuel Hanon</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Deschamps, Isabelle" sort="Deschamps, Isabelle" uniqKey="Deschamps I" first="Isabelle" last="Deschamps">Isabelle Deschamps</name>
</region>
<name sortKey="Shiver, John W" sort="Shiver, John W" uniqKey="Shiver J" first="John W" last="Shiver">John W. Shiver</name>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Erck, Stanley C" sort="Erck, Stanley C" uniqKey="Erck S" first="Stanley C" last="Erck">Stanley C. Erck</name>
</region>
<name sortKey="Gerberding, Julie L" sort="Gerberding, Julie L" uniqKey="Gerberding J" first="Julie L" last="Gerberding">Julie L. Gerberding</name>
<name sortKey="Spencer, Julia A" sort="Spencer, Julia A" uniqKey="Spencer J" first="Julia A" last="Spencer">Julia A. Spencer</name>
</country>
<country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Ivol, Sabrina" sort="Ivol, Sabrina" uniqKey="Ivol S" first="Sabrina" last="Ivol">Sabrina Ivol</name>
</region>
<name sortKey="Van Hoof, Johan" sort="Van Hoof, Johan" uniqKey="Van Hoof J" first="Johan" last="Van Hoof">Johan Van Hoof</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000006 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000006 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32348165
   |texte=   Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32348165" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki